Please ensure Javascript is enabled for purposes of website accessibility

Human Genome's Hep C Drug Is Halfway Home

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One trial down, one to go for Human Genome Sciences.

Human Genome Sciences (NASDAQ:HGSI) is halfway home. The company's hepatitis C drug, Albuferon, passed its first phase 3 trial test yesterday, but the harder test is yet to come.

In a trial on patients infected with genotypes 2 and 3 of the hepatitis C virus, Albuferon worked just as well as Roche's Pegasys. (Genotypes refer to the virus's different genetic variations.) Fortunately, it didn't have to work better than Pegasys, because it's given every other week. The other interferon treatments, Pegasys and Schering-Plough's (NYSE:SGP) Pegintron, require weekly shots. Since injecting interferon causes unpleasant side effects, halving the number of injections should be a great selling point.

Still, to get approved by the Food and Drug Administration, Human Genome Sciences and its marketing partner Novartis (NYSE:NVS) will need to show that the drug can treat genotype 1 patients as well -- especially since that's the most common genotype in the U.S.

Genotype 1 is also harder to treat, requiring 48 weeks of treatment versus the 24 weeks that patients infected with genotype 2 and 3 must undergo. Considering the issues that Albuferon has had with side effects -- a higher dose had to be scaled back during this trial because of serious pulmonary side effects -- the drug isn't out of the woods yet.

Investors won't have to wait too long to find out whether Albuferon is up to the task. The results from the trial testing genotype 1 patients are due in March.

Human Genome Sciences also has to worry about up-and-coming drugs like Schering's boceprevir and Vertex Pharmaceuticals' (NASDAQ:VRTX) and Johnson & Johnson's (NYSE:JNJ) telaprevir. These are being tested in combination with Pegasys and Pegintron. When they make it to market, doctors will likely favor the pair tested in clinical trials, potentially leaving Albuferon out in the cold. HGS can of course run trials testing Albuferon with boceprevir and telaprevir, but its developers aren't likely to be interested until Albuferon has proven its worth.

Fellow Fool Brian Lawler called it right earlier this year, when he said Human Genome Sciences was overpriced with an $800 million market cap. Now, with a market cap far less than $300 million, and one clinical trial under its belt, Human Genome Sciences is looking a little more investment-worthy. Just don't put all your eggs in its basket.

Vertex Pharmaceuticals is a Motley Fool Rule Breakers selection. Discover the latest hot drug stocks and other cutting-edge companies the team has picked with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is an Income Investor recommendation. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.30 (-1.10%) $-1.84
Novartis AG Stock Quote
Novartis AG
NVS
$85.68 (0.12%) $0.10
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$294.52 (0.81%) $2.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.